ESSA Pharma Completes XenoTherapeutics Acquisition
ESSA Pharma Inc. (NASDAQ: EPIX) has recently finalized its acquisition by XenoTherapeutics. This strategic move aims to enhance the capabilities of both companies in their respective fields of research and development.
Details of the Acquisition
Xeno Acquisition Corp., a subsidiary of XenoTherapeutics, acquired all outstanding common shares of ESSA for about US$0.1242 per share. In addition to this price, each share comes with a contingent value right (CVR), offering potential payments of up to US$0.14 per CVR, depending on certain conditions post-acquisition. This could mean a significant aggregate potential payout of about US$6.7 million to eligible CVR holders.
Approval and Final Steps
On October 7, 2025, the Supreme Court of British Columbia granted approvals for the acquisition process. Subsequently, ESSA has initiated the delisting process with the Nasdaq Capital Market, informing them of its decision to terminate the registration of its common shares. This termination is expected to be finalized approximately ten days after the acquisition closes.
Advisors for the Transaction
For this significant acquisition, ESSA received expert guidance. Leerink Partners LLC acted as the exclusive financial advisor, while Blake, Cassels & Graydon, LLP and Skadden, Arps, Slate, Meagher & Flom LLP provided Canadian and U.S. legal counsel respectively.
About ESSA Pharma Inc.
ESSA Pharma has established itself in the pharmaceutical landscape with a focus on cutting-edge therapies aimed at treating prostate cancer. The company stands at the forefront of developing novel medical solutions that cater to a significant patient demographic.
Continuing Impact in Research
The newly formed alliance with XenoTherapeutics marks a new chapter in ESSA's journey, empowering it to advance research and broaden its therapeutic offerings. This partnership promises to leverage the strengths of both organizations to optimize treatment innovations.
About XenoTherapeutics, Inc.
XenoTherapeutics operates as a research foundation concentrating on the scientific progress of xenotransplantation. Its mission includes research, clinical developments, and public education, striving to pave the way for breakthroughs in medical treatments.
Frequently Asked Questions
1. What is the significance of the acquisition?
The acquisition allows ESSA Pharma to enhance its research capabilities and broaden its therapeutic areas, particularly in prostate cancer treatment and related fields.
2. How will this affect the stock of ESSA Pharma?
The delisting from Nasdaq may impact stock valuations temporarily, but the acquisition aims to position the company for future growth and stability.
3. What are contingent value rights (CVRs)?
CVRs are a form of financial right that entitles shareholders to certain payments depending on defined conditions—here, based on the future success of the acquisition.
4. Who are the primary advisors for this acquisition?
Leerink Partners LLC served as the financial advisor, while two law firms provided necessary legal counsel for both Canadian and U.S. regulations.
5. What can be expected from ESSA post-acquisition?
Post-acquisition, ESSA is expected to focus on expanding its research capabilities and potentially introducing innovative therapies, leveraging its partnership with XenoTherapeutics.
